AbstractBackgroundCorticobasal syndrome (CBS) is a neurodegenerative disease related to multiple underlying pathologies, including four‐repeat (4R) tauopathies, namely corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP), Alzheimer’s disease (AD), among others. The Movement Disorders Society‐PSP clinical criteria proposed a diagnostic category “probable 4R‐tauopathy” to include the phenotypic overlap between PSP and CBD. These criteria were specific for 4R‐tauopathies in a previous post‐mortem validation study. We aimed to investigate this proposed criteria in a cohort of patients clinically diagnosed with probable CBS, comparing the CBS‐4R tau group regarding neurological assessment, brain atrophy patterns, functional and disease‐specific imaging biomarkers. Also, we compared this group with CBS patients that matched the clinical research (cr) criteria for CBD.MethodThirty‐two patients diagnosed with probable CBS were prospectively enrolled and clinically evaluated. They were split into those who fulfilled criteria for probable 4R‐tauopathy (CBS‐4RT = 12) and probable CBD (CBS‐CBD = 28). They underwent [18F]fluorodeoxyglucose‐positron emission tomography (FDG‐PET) and [11C]Pittsburgh Compound‐B (PIB‐PET) on a hybrid PET‐MRI to assess their amyloid status. PIB‐PET images were classified individually based on visual and 3D‐SSP semi‐quantitative analysis. Quantitative group analyses were performed with SPM12, to check both brain atrophy patterns using voxel‐based morphometry (VBM), and regional brain hypometabolism patterns with FDG‐PET. A healthy control group of 30 subjects, matched by age and education, was also included.ResultOnly one patient classified as CBS‐4RT was positive at PIB‐PET (p = 0.010), compared to 12 among 28 CBS‐CBD subjects (p = 0.458). The CBS‐4RT clinical classification had 52.6% sensitivity, 92.3% specificity, and 68.7% accuracy in predicting a negative PIB‐PET result. Also, CBS‐4RT patients presented dysarthria (p = 0.017) and motor perseveration (p = 0.032) more often than the whole group. CBS‐4RT patients showed asymmetric hypometabolism in the inferior, middle, and superior frontal gyri, supplementary motor area, and caudate compared to controls. They also demonstrated brain atrophy in the superior and inferior frontal gyri and basal ganglia.ConclusionThe new proposed clinical 4R‐tauopathies criteria demonstrated high specificity to detect amyloid‐negative CBS patients. Patients fulfilling the criteria presented specific metabolic and volumetric patterns. Moreover, they presented clinical characteristics such as dysarthria and motor perseveration previously related to tauopathies.
Read full abstract